Recent 8-K filings for SION
Highest-materiality recent filing
Sionna's SION-719 Phase 2a misses sweat chloride endpoint; program halted as add-on
- SION-719 Phase 2a missed key endpoint: -1.0 mmol/L placebo-adjusted sweat chloride change (p=0.7); not advancing as add-on to SOC.
- Phase 1 of SION-451 dual combos met safety/PK goals; SION-451 + SION-2222 preferred; evaluating next steps.
-
Sionna's SION-719 Phase 2a misses sweat chloride endpoint; program halted as add-on
SION-719 Phase 2a missed key endpoint: -1.0 mmol/L placebo-adjusted sweat chloride change (p=0.7); not advancing as add-on to SOC.
-
Sionna Therapeutics Q1 net loss $26.8M; Phase 2a enrollment completed for SION-719
Net loss of $26.8M for Q1 2026, compared to $16.5M in Q1 2025.
-
Sionna Q3 net loss $20.3M; starts Phase 2a trial for SION-719; cash runway into 2028
Net loss of $20.3M in Q3 2025 versus $25.4M in Q3 2024; R&D expenses fell to $16.0M from $24.6M due to prior year license charge.
-
Sionna Therapeutics Q2 net loss $18.1M; positive Phase 1 data for NBD1 stabilizers
Net loss $18.1M in Q2 2025 vs $8.6M in Q2 2024; R&D expenses $15.4M.
-
Both SION-719 and SION-451 were generally well tolerated with no serious adverse events or discontinuations.
-
Net loss of $16.5M for Q1 2025, up from $11.8M in Q1 2024; R&D expenses $13.7M vs $10.2M.
-
Net loss Q4 2024 $15.8M, full year $61.7M vs $47.3M in 2023; R&D spend $57.3M.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event earnings